Cedars-Sinai Medical Center

The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.

The Croatan algorithm uses the random forest machine learning method to evaluate guide RNAs for use in CRISPR knockout experiments.

The projects focus on early treatment of prostate cancer and cataloguing mutations in difficult-to-diagnose diseases, among other things. 

Called Cedars-Sinai Precision Health, the program aims to promote novel technologies and approaches for personalized medicine at the institution.

The healthcare provider organizations are tasked with managing patient enrollment in the Precision Medicine Initiative.

The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.

The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.

NEW YORK (GenomeWeb News) – Cedars-Sinai Medical Center is creating a new institute within the Cedars-Sinai Heart Institute that will apply proteomics technologies and methods in basic, experimental, and clinical medicine research projects, a Cedars-Sinai executive told GenomeWeb Daily News

Exosome Diagnostics said this week that Cedars-Sinai Medical Center will be an early-access user of the company's exosome RNA biofluid extraction kits for biomarker discovery in neo-natal and other disease settings.

A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.